Don't Expect the Antibiotic Plazomicin to Be Added to Your Hospital Formulary
You'll see the new aminoglycoside, plazomicin (Zemdri, ZEM-dree), promoted for carbapenem-resistant Enterobacteriaceae (CRE).
It works like other aminoglycosides and has the same side effects...nephrotoxicity, ototoxicity, etc.
The difference is that plazomicin isn't as affected by aminoglycoside-modifying enzymes...the most common cause of aminoglycoside resistance to E. coli and other Enterobacteriaceae.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote